Dimi @Dimkell

@jrkelly We are due a rebrand

I grew up in a small mining town in the Copperbelt in Zambia. I remember being taught about HIV in first grade and the ads on every billboard about using condoms. This is a huge deal for drug accessibility. It’s true that the future is here it’s just not evenly distributed. Often science and engineering isn’t the barrier its policy and regulation.

keyboard_arrow_left Previous keyboard_arrow_right Next

I’m excited about the next decade in biopharma. We’ll find more drug targets and we’ll get better at binding them and reducing off-target effects. The major bottlenecks are not in finding promising candidates.

Nature Reviews Drug Discovery @NatRevDrugDisc

3 days ago

The evolving landscape of drug targets nature.com/articles/s4157… rdcu.be/22o1FPpNJ3Ga In the past 25 years, advances in areas such as genomics and the diversification of therapeutic modalities have expanded the drug target landscape, which now includes ~700 targets mapped here

5 96 389 79K 296

X is about to get a whole new genre of content.

Dexerto @Dexerto

7 days ago

New York City is rolling out public toilets that only give you 10 minutes to finish An announcer warns if time is running out before the door slides open, potentially exposing users to the public

keyboard_arrow_left Previous keyboard_arrow_right Next

1K 949 47K 10.9M 4K

New York City is rolling out public toilets that only give you 10 minutes to finish An announcer warns if time is running out before the door slides open, potentially exposing users to the public

keyboard_arrow_left Previous keyboard_arrow_right Next

Cool list. I know startups working on 2 and 6 with great teams. 7 seems oddly out of place compared to the rest. Other ones that didn’t make the list that would be good to see: predict a precise cellular response to an arbitrary input, predict development from a genome, create a synthetic cell that can propagate, predict all on and off target effects of proteins in an organism.

Worth a read! “>one day assistant asks obvious question >"how do you know your intervention actually improves the far future?" >silence >open spreadsheet >increase column width >add confidence interval >assistant asks again >"no, I mean how do you know the sign is positive?" >stare into cosmic light cone”

banteg @banteg

7 days ago

>be me >discover effective altruism >apparently normal charity is inefficient >why donate to random sad thing when spreadsheet can tell you optimal sad thing >fair enough >buy mosquito nets >save lives >numbers look good >feel powerful >couple years later >someone asks an

759 2K 20K 2.8M 12K

Secret cheat code about to be unlocked...

Finally breaking out of our shell 🐣

Chris Barber @chrisbarber

a week ago

I made a list of great startups to join. It's called the Breakout List. The list has 92 companies. These are the 20 with 25 or fewer employees: - Hone (@moritz_stephan, @CarloWillem, @oqbrady) - Normal (@ansonyuu, @hudzah) - Standard Intelligence (@G413N, @devanshpandey) - Tacit

47 86 1K 566K 3K

@uninsightful @usv Exciting times. Having been on the other side of the table in your process, I’m certain you will be very successful in this role

@brexton Brilliant

The impending situation in biosimilars is not getting the attention it deserves. There has been a ton of focus from the federal government (with good reason) on small molecule generics that mostly come from India and China. Biologics (and biosimilars by extension) manufacturing is structurally different. These facilities cost billions and take many years to build. We don’t have anywhere near the required capacity for biosimilars in the US and hardly any are manufactured here today. To address this issue with traditional manufacturing technologies we would need to start building this infrastructure yesterday. But let’s say by some miracle we did that, the costs would be 2-3x those in China. That isn’t acceptable. We need technologies that enable domestic manufacturing while simultaneously reducing costs (disclaimer: that’s what we do at Neion Bio). We’ve seen what happens when we hand over the manufacturing of critical materials to other countries. There is nothing more critical to life, liberty and the pursuit of happiness than human health.

The Wall Street Journal @WSJ

2 weeks ago

A new industry report shows 90% of major brand-name biologic drugs losing exclusivity over the next decade have no low-cost competitors in development. on.wsj.com/4gTivTi

13 26 53 83K 22

@ZacharyBrennan Crisis is the right framing.

It is obviously cool that we are starting to apply AI to interesting math problems but I’m kinda nostalgic for the days of pen and paper. In undergrad we had to sit and prove the closure problem (you average NS and create more unknowns than equations making it not solvable other than with approximations). I remember being so happy that I snapped a photo of it.

keyboard_arrow_left Previous keyboard_arrow_right Next

OpenAI @OpenAI

2 weeks ago

We’re sharing a solution to the Navier-Stokes Millennium Prize Problem, one of the deepest problems at the frontier of mathematics. The proof was produced by a group of agents, using an OpenAI next-generation model significantly more capable than GPT-6 Astra. The problem

6K 20K 121K 74.8M 31K

@brad_rothenberg One of my favorite planes. Some parts were designed to be loose fitting because they would heat up and expand so much during flight. It had to take off light because it would leak fuel on the ground so every mission started with a mid air refuel.

So true. The product is the factory as Elon would say

Caitlin Bolnick Rellas @caitlinbolnick1

3 weeks ago

You cannot become a “hard tech” company without becoming a manufacturing company. You cannot become a great manufacturing co without becoming exceptional at physical operations. Technology alone is not enough to win in the space. If your investor does not understand what this

31 16 334 54K 72

Here's a glimpse behind the curtain at Neion Bio. In biotech, we often take manufacturing for granted but it is fundamental to innovation. "Those serious about software should make their own hardware." The same is true in biology. The manufacturing of life-saving biopharma medicines has been stagnant for decades. Legacy technologies that rely on a single type of cell reached diminishing returns in the late 2000s. In order to squeeze out more we relocated these factories in areas with lower costs ex-US. Spending billions to rebuild this infrastructure domestically using largely the same legacy technologies is fighting a losing battle. Sure there may be an incremental improvement here and there but these facilities will be uncompetitive as soon as they go live (if they ever go live). We now have the ability to efficiently and accurately reprogram complex biological systems, so why are we restricting ourselves to the small sliver of biology that happened to work 50 years ago? Thanks @teleodaniel and @EricDai_BioE for helping tell our story.

Daniel Shur @teleodaniel

3 weeks ago

Producing the 3 to 5 grams of a biologic needed for IND-enabling studies costs millions of dollars using traditional CHO manufacturing. A single egg, meanwhile, contains 6 grams of protein, costs just 10 cents, and requires only chicken feed and water as inputs. Neion Bio is

0 4 7 2K 1

Producing the 3 to 5 grams of a biologic needed for IND-enabling studies costs millions of dollars using traditional CHO manufacturing. A single egg, meanwhile, contains 6 grams of protein, costs just 10 cents, and requires only chicken feed and water as inputs. Neion Bio is taking advantage of this incredible technology to turn chickens into drug factories. And they’ve already signed a commercial deal with a drugmaker to produce biosimilars. With AI leaders promising to unleash countless new therapies, we’re going to need to scale up our manufacturing. That sci-fi future may be one where we stop producing drugs in huge steel tanks, and instead start farming them like we do our food. We sat down with co-founders Dimi Kellari and Sam Levin to discuss this future. [Disclosure: I’m an investor, though I wasn’t at the time of recording.] Watch the full episode below, or look up Free Radicals (@FreeRadicalsBio) on your favorite podcasting platform. Thank you to @SynBioBeta for hosting us! 0:00 Intro 1:07 What Neion Bio does 4:53 How the founders arrived at synthetic biology and chickens 10:21 Biosimilars as Neion’s first commercial market 13:30 Why farming drugs is a viable path to reshoring biomanufacturing 18:38 Neion’s technical moat & why engineering birds is difficult 25:50 Advantages of chicken-based manufacturing 30:06 Why CHO manufacturing became the industry standard 33:21 What it takes to disrupt CHO manufacturing 37:57 What it means to program biology 42:48 Skepticism around this new manufacturing approach 47:00 Applying tech principles to biotech 55:34 Natural intelligence vs artificial intelligence 57:14 The future of farming drugs & programmable chickens

This might seem simple but it’s really damn hard. Congrats @jaimalik and team - this is what innovating in the physical world looks like…

Jai Malik @jaimalik

3 weeks ago

as Amca matures, I'm excited to start peeling back what we've been up to. New software, a LOT more hardcore engineering - some of which hasn't been done in decades, and hopefully happy customers. Exciting news coming over the next few months. More to follow soon...

14 16 152 22K 22

@Varungupta 100%